Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DxS enters Scorpions deal with SIRS-Lab

This article was originally published in Clinica

Executive Summary

Manchester, UK-based molecular diagnostics firm DxS has licensed its Scorpions real-time PCR technology to German sepsis specialist SIRS-Lab for an undisclosed fee. The EU-wide agreement allows SIRS-Lab to incorporate DxS’ technology into its Siqnature sepsis prediction and monitoring test, which it aims to make commercially available in 2009. The Siqnature allows the early detection of sepsis by differentiating between infectious and non-infectious states in patients – the test is based on proprietary transcriptomic biomarkers that indicate sepsis earlier and more reliably than currently possible, claims Jena-based SIRS-Lab. The deal between the two firms also includes an option for worldwide IVD utilisation of the Scorpions technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel